Hunt under pressure over plans to quit EMA
Britain could be in “second rank” of medicines access, warn MPs.
X
Hunt under pressure over plans to quit EMA
https://pharmaphorum.com/news/mps-concerned-drugs-access-post-brexit/
ema
EU drug regulators concerned about Brexit impact
European regulators concerned over impact of EMA move.
Boehringer files Humira biosimilar in US and EU
New threat to AbbVie’s top-seller.
Fast-track appraisals and Managed Access Agreements
Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
High-value, high-cost drugs: how to pay for them
Experts call for urgent development of new drug funding mechanisms.
EU regulators back Lilly’s blockbuster RA pill
Pill could generate $2 billion sales.
A new age: the real-world development pathway
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
FDA and EMA to work more closely on paediatric drug regulation
FDA and EMA hope to streamline development of paediatric plans.
